Health Economics›Breast cancer›Neoadjuvant chemotherapy, sequential regimens

Neoadjuvant chemotherapy, sequential regimens

Breast cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
D-FEC+Bev Variant #01	—	R 65 404	21d	—	—	~3	~R 136 240 indirect	—
D-AC+Bev Variant #01	—	R 33 029	21d	—	—	~6	~R 192 087 indirect	—
nP-EC Variant #01	—	R 22 380	21d	—	—	~12	~R 249 955 indirect	—
D-FEC Variant #01	—	R 5 432	21d	—	—	~3	~R 16 295 PFS proxy · indirect	1
EC-D Variant #01	—	R 5 248	21d	—	—	~4	~R 20 991 PFS proxy · indirect	1
T-FAC Variant #01	—	R 4 099	21d	—	—	~4	~R 16 396 indirect	—
AC-D Variant #01	—	R 3 692	21d	—	—	~4	~R 14 767 PFS proxy · indirect	2
EC-ddT Variant #01	—	R 3 633	21d	—	—	~4	~R 14 534 indirect	—
ddT-EC Variant #01	—	R 3 633	21d	—	—	~4	~R 14 534 indirect	—
T-FEC Variant #01	—	R 3 122	21d	—	—	~12	~R 17 385 indirect	—
D-AC Variant #01	—	R 3 042	21d	—	—	~4	~R 12 170 indirect	—
T-EC Variant #01	—	R 2 938	28d	—	—	~12	~R 16 649 indirect	—
EC-T Variant #01	—	R 2 554	21d	—	—	~12	~R 15 113 PFS proxy · indirect	2
AC-T Variant #01	—	R 2 077	21d	—	—	~4	~R 8 309 PFS proxy · indirect	2
T-AC Variant #01	—	R 1 382	21d	—	—	~12	~R 10 425 indirect	—

15 of 15 regimens shown